Biotechnology company NKMax America stated on Tuesday that it has dosed its first patient with plaque psoriasis under its SNK01-MX03 phase I clinical trial of SNK at Angeles Hospital,Tijuana, Mexico.
The company said SNK is an ex vivo expanded autologous natural killer cell therapeutic manufactured by harvesting a small number of a patient's immune cells. After harvesting, NK cells are separated from the blood, purified, activated and expanded in a cGMP facility. The activated NK cells (SNK) are reinfused in the patient to suppress the inflammatory response attributed to psoriasis.
This single centre, dose escalation SNK01-MX03 phase I clinical trial will evaluate SNK administered intravenously once a week for four weeks at three different dosing levels.
According to the company, it will enroll nine subjects in the trial to investigate the safety and tolerability of SNK in adults with mild to severe plaque psoriasis.
In conjunction, the SNK study for psoriasis is currently recruiting participants the state-of-the-art Angeles hospital in Tijuana, Mexico, concluded the company.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval